Search PubMed⌕ Search

PubMed · 7761892

Eating disorders.

Abstract

The main forms of eating disorders are anorexia and bulimia nervosa and obesity. The clinical features, aetiology, treatment and prognosis of anorexia and bulimia nervosa are described to highlight the similarities and differences between these two conditions. Both conditions affect predominantly the young female population with body image disturbance as one of the core symptoms. Whilst the body weight of anorexics are by definition low, most bulimics have normal or near normal body weight. Sufferers of anorexia nervosa tend to deny their illness while those with bulimia are often miserable and acutely aware of their eating difficulties. The aetiological factors in both conditions overlap to a large extent. The outcome of treatment for bulimia is reportedly better than that of anorexia nervosa. Obese people often become depressed and anxious as a result of low self-esteem causing them to seek psychiatric treatment. The severely obese who are placed on very low calorie diets may develop adverse emotional disturbances whilst weight gain may follow a major depressive illness or develop as a side effect of psychotropic medications. A subgroup of the obese population engage in frequent binge eating and preliminary criteria are being developed for this condition called "binge eating disorder". Behaviour therapy is the treatment of choice for obesity. Other forms of treatment include individual and group psychotherapy, use of appetite suppressants and in the severely obese, surgical methods.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B L Low. 1994. Eating disorders.. https://pubmed.ncbi.nlm.nih.gov/7761892/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Understanding eating disorders.

The outcome in eating disorders remains poor and commonly used methods of treatment have little, if any effect. It is suggested that this situation has emerged because of the failure to realize that the symptoms of eating disorder patients are epiphenomena to starvation and the associated disordered eating. Humans have evolved to cope with the challenge of starvation and the neuroendocrine mechanisms that have been under this evolutionary pressure are anatomically versatile and show synaptic plasticity to allow for flexibility. Many of the neuroendocrine changes in starvation are responses to the externally imposed shortage of food and the associated neuroendocrine secretions facilitate behavioral adaptation as needed rather than make an individual merely eat more or less food. A parsimonious, neurobiologically realistic explanation why eating disorders develop and why they are maintained is offered. It is suggested that the brain mechanisms of reward are activated when food intake is reduced and that disordered eating behavior is subsequently maintained by conditioning to the situations in which the disordered eating behavior developed via the neural system for attention. In a method based on this framework, patients are taught how to eat normally, their physical activity is controlled and they are provided with external heat. The method has been proven effective in a randomized controlled trial.

Anorexia↗

Anorexia in cancer: role of feeding-regulatory peptides.

Anorexia is one of the most common symptoms in advanced cancer and is a frequent cause of discomfort for cancer patients and their families. The pathogenesis of cancer anorexia is multi-factorial and involves most of the hypothalamic neuronal signalling pathways modulating energy homeostasis. It is considered to be the result of a failure of usual appetite and satiety signals. Loss of appetite can arise from decreased taste and smell of food, as well as from dysfunctional hypothalamic signalling pathways and cytokine production. Cytokines in particular, appear to play a key role in energy balance through persistent activation of the melanocortin system and inhibition of the neuropeptide Y pathway. The imbalance between anorexigenic and orexigenic peptides leads to suppression of appetite, and increased satiety and satiation associated with marked weight loss and decline in physical performance. High levels of serotonin also appear to contribute to these effects and recent findings implicate corticotropin-releasing factor in the pathogenesis of cancer anorexia as well. Despite significant advances in our understanding of the regulation of food intake and energy expenditure, few effective therapies are available. A better appreciation of the molecular and neuronal mechanisms that control body weight homeostasis may lead to the development of new therapies for improving the survival and quality of life of these patients.

Anorexia↗

Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients.

Anorexia, or loss of appetite, is a troubling symptom for many patients with advanced cancer. The early observation that breast cancer patients, who were prescribed megestrol acetate as a cancer treatment, went on to increase their appetite and gain weight has given rise to a large number of clinical trials that have tested this progestational drug as a palliative agent for the cancer anorexia/weight loss syndrome. This review focuses on these trials, summarizing their findings and providing a practical approach for prescribing megestrol acetate to advanced cancer patients who suffer from the cancer anorexia/weight loss syndrome.

Anorexia↗